The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
A large study of 30,000 adults diagnosed with ADHD in the U.K. found women with ADHD died roughly nine years younger than women without a diagnosis. Men had about a seven-year shorter lifespan.